FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms
Cardiotoxicity remains a major limiting factor in the clinical implementation of anthracycline chemotherapy. Though the etiology of doxorubicin-dependent heart damage has yet to be fully elucidated, the ability of doxorubicin to damage DNA and trigger oxidative stress have been heavily implicated in...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Redox Biology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231725000400 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1823864384094470144 |
---|---|
author | Manish Kumar Abhishek Singh Sengar Anushree Lye Pranesh Kumar Sukhes Mukherjee Dinesh Kumar Priyadip Das Suvro Chatterjee Adele Stewart Biswanath Maity |
author_facet | Manish Kumar Abhishek Singh Sengar Anushree Lye Pranesh Kumar Sukhes Mukherjee Dinesh Kumar Priyadip Das Suvro Chatterjee Adele Stewart Biswanath Maity |
author_sort | Manish Kumar |
collection | DOAJ |
description | Cardiotoxicity remains a major limiting factor in the clinical implementation of anthracycline chemotherapy. Though the etiology of doxorubicin-dependent heart damage has yet to be fully elucidated, the ability of doxorubicin to damage DNA and trigger oxidative stress have been heavily implicated in the pathogenesis of chemotherapy-associated cardiomyopathy. Here, we demonstrate that fibronectin type III domain-containing protein 5 (FNDC5), the precursor protein for myokine irisin, is depleted in the hearts of human cancer patients or mice exposed to chemotherapeutics. In cardiomyocytes, restoration of FNDC5 expression was sufficient to mitigate reactive oxygen species (ROS) accumulation and apoptosis following doxorubicin exposure, effects dependent on the irisin encoding domain of FNDC5 as well as signaling via the putative irisin integrin receptor. Intriguingly, we identified two parallel signaling cascades impacted by FNDC5 in cardiomyocytes: the ROS-driven intrinsic mitochondrial apoptosis pathway and the ROS-independent Ataxia Telangiectasia and Rad3-Related Protein (ATR)/Checkpoint Kinase 1 (Chk1) pathway. In fact, FNDC5 forms a co-precipitable complex with Chk1 alluding to possible intracellular actions for this canonically membrane-associated protein. Whereas FNDC5 overexpression in murine heart was cardioprotective, introduction of FNDC5-targeted shRNA into the myocardium was sufficient to trigger Bax up-regulation, ATR/Chk1 activation, oxidative stress, cardiac fibrosis, loss of ventricular function, and compromised animal survival. The detrimental impact of FNDC5 depletion on heart function could be mitigated via treatment with a Chk1 inhibitor identifying Chk1 hyperactivity as a causative factor in cardiac disease. Though our data point to the potential clinical utility of FNDC5/irisin-targeted agents in the treatment of chemotherapy-induced cardiotoxicity, we also found significant down regulation in FNDC5 expression in the hearts of aged mice that attenuated the cardioprotective impacts of FNDC5 overexpression following doxorubicin exposure. Together our data underscore the importance of FNDC5/irisin in maintenance of cardiac health over the lifespan. |
format | Article |
id | doaj-art-2e61cd76cef44255b3e7d5e5d9253563 |
institution | Kabale University |
issn | 2213-2317 |
language | English |
publishDate | 2025-03-01 |
publisher | Elsevier |
record_format | Article |
series | Redox Biology |
spelling | doaj-art-2e61cd76cef44255b3e7d5e5d92535632025-02-09T05:00:25ZengElsevierRedox Biology2213-23172025-03-0180103527FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanismsManish Kumar0Abhishek Singh Sengar1Anushree Lye2Pranesh Kumar3Sukhes Mukherjee4Dinesh Kumar5Priyadip Das6Suvro Chatterjee7Adele Stewart8Biswanath Maity9Centre of Biomedical Research, Raebareli Road, Lucknow, Uttar Pradesh, 226014, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, IndiaCentre of Biomedical Research, Raebareli Road, Lucknow, Uttar Pradesh, 226014, IndiaCentre of Biomedical Research, Raebareli Road, Lucknow, Uttar Pradesh, 226014, India; Department of Biological Sciences, Bose Institute, EN 80, Sector V, Kolkata, West Bengal, 700091, IndiaInstitute of Pharmaceutical Science, University of Lucknow, Uttar Pradesh, 226007, IndiaDepartment of Biochemistry, AIIMS Bhopal, Saketnagar, Bhopal, Madhya Pradesh, IndiaCentre of Biomedical Research, Raebareli Road, Lucknow, Uttar Pradesh, 226014, IndiaDepartment of Chemistry, SRM Institute of Science and Technology, Tamil Nadu, 603203, IndiaDepartment of Biotechnology, Burdwan University, West Bengal, 713104, IndiaDepartment of Neuroscience & Pharmacology, University of Iowa, Iowa City, IA, 52242, USACentre of Biomedical Research, Raebareli Road, Lucknow, Uttar Pradesh, 226014, India; Department of Biological Sciences, Bose Institute, EN 80, Sector V, Kolkata, West Bengal, 700091, India; Department of Biological Sciences Bose Institute Unified Academic Campus EN 80, Sector V, Kolkata, 700091, WB, India.bmaity@jcbose.ac.inCardiotoxicity remains a major limiting factor in the clinical implementation of anthracycline chemotherapy. Though the etiology of doxorubicin-dependent heart damage has yet to be fully elucidated, the ability of doxorubicin to damage DNA and trigger oxidative stress have been heavily implicated in the pathogenesis of chemotherapy-associated cardiomyopathy. Here, we demonstrate that fibronectin type III domain-containing protein 5 (FNDC5), the precursor protein for myokine irisin, is depleted in the hearts of human cancer patients or mice exposed to chemotherapeutics. In cardiomyocytes, restoration of FNDC5 expression was sufficient to mitigate reactive oxygen species (ROS) accumulation and apoptosis following doxorubicin exposure, effects dependent on the irisin encoding domain of FNDC5 as well as signaling via the putative irisin integrin receptor. Intriguingly, we identified two parallel signaling cascades impacted by FNDC5 in cardiomyocytes: the ROS-driven intrinsic mitochondrial apoptosis pathway and the ROS-independent Ataxia Telangiectasia and Rad3-Related Protein (ATR)/Checkpoint Kinase 1 (Chk1) pathway. In fact, FNDC5 forms a co-precipitable complex with Chk1 alluding to possible intracellular actions for this canonically membrane-associated protein. Whereas FNDC5 overexpression in murine heart was cardioprotective, introduction of FNDC5-targeted shRNA into the myocardium was sufficient to trigger Bax up-regulation, ATR/Chk1 activation, oxidative stress, cardiac fibrosis, loss of ventricular function, and compromised animal survival. The detrimental impact of FNDC5 depletion on heart function could be mitigated via treatment with a Chk1 inhibitor identifying Chk1 hyperactivity as a causative factor in cardiac disease. Though our data point to the potential clinical utility of FNDC5/irisin-targeted agents in the treatment of chemotherapy-induced cardiotoxicity, we also found significant down regulation in FNDC5 expression in the hearts of aged mice that attenuated the cardioprotective impacts of FNDC5 overexpression following doxorubicin exposure. Together our data underscore the importance of FNDC5/irisin in maintenance of cardiac health over the lifespan.http://www.sciencedirect.com/science/article/pii/S2213231725000400 |
spellingShingle | Manish Kumar Abhishek Singh Sengar Anushree Lye Pranesh Kumar Sukhes Mukherjee Dinesh Kumar Priyadip Das Suvro Chatterjee Adele Stewart Biswanath Maity FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms Redox Biology |
title | FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms |
title_full | FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms |
title_fullStr | FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms |
title_full_unstemmed | FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms |
title_short | FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms |
title_sort | fndc5 irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ros dependent and independent mechanisms |
url | http://www.sciencedirect.com/science/article/pii/S2213231725000400 |
work_keys_str_mv | AT manishkumar fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms AT abhisheksinghsengar fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms AT anushreelye fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms AT praneshkumar fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms AT sukhesmukherjee fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms AT dineshkumar fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms AT priyadipdas fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms AT suvrochatterjee fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms AT adelestewart fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms AT biswanathmaity fndc5irisinmitigatesthecardiotoxicimpactsofcancerchemotherapeuticsbymodulatingrosdependentandindependentmechanisms |